Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.
新澤西州禾倫，2024年12月10日（全球新聞網）-- Tevogen Bio（"Tevogen"或"Tevogen Bio Holdings Inc."）（納斯達克：TVGN），是一家臨床階段的專業免疫治療生物技術公司，開發現成的、基因未修改的T細胞療法，用於治療傳染病和癌症，今天宣佈創始人兼首席執行官Ryan Saadi，醫學博士，公共衛生碩士，將參加2025年1月13日至16日在加利福尼亞州舊金山舉行的摩根大通醫療會議。
The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector.
摩根大通醫療會議是行業中規模最大、信息最豐富的醫療投資研討會，彙集了關鍵利益相關者，討論行業中的創新和進展。
For inquiries about Tevogen Bio's JP Morgan events, please contact Communications at communications@tevogen.com
有關Tevogen Bio的摩根大通活動的諮詢，請聯繫通信部門，郵箱是communications@tevogen.com
About Tevogen Bio
關於Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen是一家臨床階段的專業免疫治療公司，利用自然界最強大的免疫武器之一，CD8+細胞毒性T淋巴細胞，開發即用型、基因未改造的精準T細胞療法，以治療感染性疾病、癌症和神經系統疾病，旨在滿足大量患者群體的重大未滿足需求。Tevogen的領導層相信，在當前醫療保健時代，可持續性和商業成功依賴於通過先進科學和創新業務模型確保患者的可及性。Tevogen已經在其概念驗證臨床試驗中報告了積極的安全數據，其主要知識產權資產完全歸公司所有，不受任何第三方許可協議的限制。這些資產包括三項已授予的專利、九項待審的美國專利和十二項非美國待審專利，其中兩項與人工智能有關。
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Tevogen由一支經驗豐富的行業領導者和傑出科學家團隊驅動，他們在藥物開發和全球產品上市方面擁有豐富經驗。Tevogen的領導層認爲，可及的個性化治療是醫學的下一個前沿，顛覆性的商業模型是維持醫療創新所必需的。
Contacts
聯繫人
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen生物通訊-半導體
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com